These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 27663208)

  • 21. Analysis of Food and Drug Administration-approved anticancer agents in the NCI60 panel of human tumor cell lines.
    Holbeck SL; Collins JM; Doroshow JH
    Mol Cancer Ther; 2010 May; 9(5):1451-60. PubMed ID: 20442306
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Failure rate: Why many cancer drugs don't receive FDA approval, and what can be done about it.
    Printz C
    Cancer; 2015 May; 121(10):1529-30. PubMed ID: 25946212
    [No Abstract]   [Full Text] [Related]  

  • 23. Post-market drug safety evidence sources: an analysis of FDA drug safety communications.
    Ishiguro C; Hall M; Neyarapally GA; Dal Pan G
    Pharmacoepidemiol Drug Saf; 2012 Oct; 21(10):1134-6. PubMed ID: 23033257
    [No Abstract]   [Full Text] [Related]  

  • 24. Researchers left to guess at outcomes of most cancer clinical trials.
    Twombly R
    J Natl Cancer Inst; 2009 Jan; 101(2):72-4. PubMed ID: 19141774
    [No Abstract]   [Full Text] [Related]  

  • 25. Is having more preapproval data the best way to assure drug safety?
    Garber AM
    Health Aff (Millwood); 2008; 27(5):w371-3. PubMed ID: 18682442
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rare cancer trial design: lessons from FDA approvals.
    Gaddipati H; Liu K; Pariser A; Pazdur R
    Clin Cancer Res; 2012 Oct; 18(19):5172-8. PubMed ID: 22718862
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Characteristics of clinical trials to support approval of orphan vs nonorphan drugs for cancer.
    Kesselheim AS; Myers JA; Avorn J
    JAMA; 2011 Jun; 305(22):2320-6. PubMed ID: 21642684
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The complexity of integrating speed and safety in drug development and approval.
    Charo RA
    JAMA Intern Med; 2013 Jul; 173(13):1165-6. PubMed ID: 23568604
    [No Abstract]   [Full Text] [Related]  

  • 29. A survey of new oncology drug approvals in the USA from 2010 to 2015: a focus on optimal dose and related postmarketing activities.
    Lu D; Lu T; Stroh M; Graham RA; Agarwal P; Musib L; Li CC; Lum BL; Joshi A
    Cancer Chemother Pharmacol; 2016 Mar; 77(3):459-76. PubMed ID: 26811176
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Discordance Between Child-Pugh and National Cancer Institute Classifications for Hepatic Dysfunction: Implications on Dosing Recommendations for Oncology Compounds.
    Elmeliegy M; Yang DZ; Salama E; Parivar K; Wang DD
    J Clin Pharmacol; 2021 Jan; 61(1):105-115. PubMed ID: 32691438
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inappropriate use of progression-free survival in cancer drug approvals.
    Naci H; Davis C
    BMJ; 2020 Mar; 368():m770. PubMed ID: 32156802
    [No Abstract]   [Full Text] [Related]  

  • 32. A review of pregnancy and lactation postmarketing studies required by the FDA.
    Krastein J; Sahin L; Yao L
    Pharmacoepidemiol Drug Saf; 2023 Mar; 32(3):287-297. PubMed ID: 36401739
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Medical device postapproval safety monitoring: where does the United States stand?
    Rajan PV; Kramer DB; Kesselheim AS
    Circ Cardiovasc Qual Outcomes; 2015 Jan; 8(1):124-31. PubMed ID: 25563662
    [No Abstract]   [Full Text] [Related]  

  • 34. A drug is not a drug is not a drug: a commentary.
    Struijker Boudier HA
    Pharmacoepidemiol Drug Saf; 2002 Sep; 11(6):437-8. PubMed ID: 12426926
    [No Abstract]   [Full Text] [Related]  

  • 35. Can We Find the Positive in Negative Clinical Trials?
    Allegra CJ; Goodwin PJ; Ganz PA
    J Natl Cancer Inst; 2019 Jul; 111(7):637-638. PubMed ID: 31077298
    [No Abstract]   [Full Text] [Related]  

  • 36. The role of the U.S. Food and Drug Administration review process: clinical trial endpoints in oncology.
    McKee AE; Farrell AT; Pazdur R; Woodcock J
    Oncologist; 2010; 15 Suppl 1():13-8. PubMed ID: 20237212
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A systematic assessment of key design and performance characteristics of drug exposure registries requested by the U.S. Food and Drug Administration.
    Zhao Y; Pinnow E; Major JM
    Pharmacoepidemiol Drug Saf; 2018 Mar; 27(3):299-306. PubMed ID: 29349833
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Oncology's first Phase 0 trial.
    Rowan K
    J Natl Cancer Inst; 2009 Jul; 101(14):978-9. PubMed ID: 19584322
    [No Abstract]   [Full Text] [Related]  

  • 39. Progress in the Fight Against Multidrug-Resistant Bacteria? A Review of U.S. Food and Drug Administration-Approved Antibiotics, 2010-2015.
    Deak D; Outterson K; Powers JH; Kesselheim AS
    Ann Intern Med; 2016 Sep; 165(5):363-72. PubMed ID: 27239977
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Characteristics of Preapproval and Postapproval Studies of Vaccines Granted Accelerated Approval by the US Food and Drug Administration.
    Egilman A; Wallach JD; Puthumana J; Zhang AD; Schwartz JL; Ross JS
    J Gen Intern Med; 2021 Oct; 36(10):3281-3284. PubMed ID: 34131876
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.